These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 25750269)

  • 21. Recent advances in therapy for glioblastoma.
    Clarke J; Butowski N; Chang S
    Arch Neurol; 2010 Mar; 67(3):279-83. PubMed ID: 20212224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.
    von Neubeck C; Seidlitz A; Kitzler HH; Beuthien-Baumann B; Krause M
    Br J Radiol; 2015 Sep; 88(1053):20150354. PubMed ID: 26159214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of low-molecular weight heparin addition to concomitant chemoradiotherapy in the treatment of glioblastoma multiforme.
    Zincircioglu SB; Kaplan MA; Isikdogan A; Cil T; Karadayi B; Dirier A; Kucukoner M; Inal A; Yildiz I; Aggil F; Donmez O; Urakci Z; Pekkolay Z; Firat U
    J BUON; 2012; 17(1):124-7. PubMed ID: 22517705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Towards tailored therapy of glioblastoma multiforme.
    Rekers NH; Sminia P; Peters GJ
    J Chemother; 2011 Aug; 23(4):187-99. PubMed ID: 21803695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
    Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
    Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients.
    Lee IY; Hanft S; Schulder M; Judy KD; Wong ET; Elder JB; Evans LT; Zuccarello M; Wu J; Aulakh S; Agarwal V; Ramakrishna R; Gill BJ; Quiñones-Hinojosa A; Brennan C; Zacharia BE; Silva Correia CE; Diwanji M; Pennock GK; Scott C; Perez-Olle R; Andrews DW; Boockvar JA
    Future Oncol; 2024 Mar; 20(10):579-591. PubMed ID: 38060340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
    Neagu MR; Reardon DA
    Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glioblastoma multiforme: evidence-based approach to therapy.
    Nicholas MK
    Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S23-7. PubMed ID: 18076314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendritic cell immunotherapy for glioblastoma.
    Polyzoidis S; Ashkan K
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
    De Vleeschouwer S; Fieuws S; Rutkowski S; Van Calenbergh F; Van Loon J; Goffin J; Sciot R; Wilms G; Demaerel P; Warmuth-Metz M; Soerensen N; Wolff JE; Wagner S; Kaempgen E; Van Gool SW
    Clin Cancer Res; 2008 May; 14(10):3098-104. PubMed ID: 18483377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New therapeutic options in therapy of glioblastoma multiforme].
    Lakomý R; Burkon P; Burkonová D; Jancálek R
    Klin Onkol; 2010; 23(6):381-7. PubMed ID: 21351415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment options for glioblastoma.
    Chamberlain MC
    Neurosurg Focus; 2006 Apr; 20(4):E19. PubMed ID: 16709025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Agenus cancer vaccine extends survival of GBM patients.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(2):252-3. PubMed ID: 24963517
    [No Abstract]   [Full Text] [Related]  

  • 37. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).
    Shibui S; Narita Y; Mizusawa J; Beppu T; Ogasawara K; Sawamura Y; Kobayashi H; Nishikawa R; Mishima K; Muragaki Y; Maruyama T; Kuratsu J; Nakamura H; Kochi M; Minamida Y; Yamaki T; Kumabe T; Tominaga T; Kayama T; Sakurada K; Nagane M; Kobayashi K; Nakamura H; Ito T; Yazaki T; Sasaki H; Tanaka K; Takahashi H; Asai A; Todo T; Wakabayashi T; Takahashi J; Takano S; Fujimaki T; Sumi M; Miyakita Y; Nakazato Y; Sato A; Fukuda H; Nomura K
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):511-21. PubMed ID: 23228988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.
    Ung N; Yang I
    J Neurooncol; 2015 Jul; 123(3):473-81. PubMed ID: 26070553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Designer therapies for glioblastoma multiforme.
    Sathornsumetee S; Rich JN
    Ann N Y Acad Sci; 2008 Oct; 1142():108-32. PubMed ID: 18990124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.